CoChat
Sign Up
Cited by 249Restless Legs Syndrome ResearchTreatment of Major DepressionParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Restless legs syndrome as side effect of second generation antidepressants

Rottach, Klaus G., Schaner, Bernhard M., Kirch, Michael H., Zivotofsky, Ari Z., Teufel, Lydia M., Gallwitz, Thorsten, Messer, Thomas·2008·Journal of Psychiatric Research
DOI 10.1016/j.jpsychires.2008.02.006
Open this paper in CoChat — free account

Abstract

Although of clinical interest, the question is still not fully answered whether antidepressants (AD) can cause or exacerbate restless legs syndrome (RLS). The literature provides contradictory information. This study addresses this problem for the class of second generation AD. In four neurological offices, all patients treated for the first time with an AD were prospectively observed with regard to the question of whether RLS occurred or pre-existing RLS worsened as a result of the medication. Because initial treatment in the participating offices is mainly executed with "modern" selective AD, the study was restricted to these drugs (fluoxetine, paroxetine, citalopram, sertraline, escitalopram, venlafaxine, duloxetine, reboxetine, and mirtazapine). In 9% of patients, RLS was recorded as a side effect related to the administration of AD. The frequency of this side effect varied among the drugs. The problem is most pronounced with mirtazapine provoking or deteriorating RLS in 28% of patients. By contrast, no case occurred during use of reboxetine. As for the other AD, the rate of newly occurred and deteriorated RLS, ranged from 5% to 10%. Typically, RLS occurred during the initial days of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2008.02.006

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mianserin and mirtazapine may induce restless legs syndrome in as many as 28% of patients.

    “Mianserin and mirtazapine may induce restless legs syndrome in as many as 28% of patients [29].”

    From Effects of Antidepressants on Sleep (2017) · cites this paper as [29]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Agargün, 2002, Restless legs syndrome induced by mirtazapine (letter), J Clin Psychiatry, 63, 1179, 10.4088/JCP.v63n1214a · DOI
  2. Akpinar, 1982, Treatment of restless legs syndrome with levodopa plus benserazide, Arch Neurol, 39, 739, 10.1001/archneur.1982.00510230065027 · DOI
  3. Bakh, 2002, Mirtazapine may have the propensity for developing a restless legs syndrome? A case report, Psychiatry Clin Neurosci, 56, 209, 10.1046/j.1440-1819.2002.00955.x · DOI
  4. Bakshi, 1996, Fluoxetine and restless legs syndrome, Journal of Neurology Sci, 142, 151, 10.1016/0022-510X(96)00180-3 · DOI
  5. Bonin, 2000, Mirtazapine and restless legs syndrome: a case report (letter), Therapie, 55, 655
  6. Brown, 2005, Antidepressant medication use and restless legs syndrome in patients presenting with insomnia, Sleep Medicine, 6, 443, 10.1016/j.sleep.2005.03.005 · DOI
  7. Chang, 2006, Does domperidone potentiate mirtazapine associated restless legs syndrome?, Prog Neuropsychopharmacol Biol Psychiatry, 30, 316, 10.1016/j.pnpbp.2005.10.001 · DOI
  8. Chen, 2003, Zonisamide-induced restless legs syndrome, Neurology, 60, 147, 10.1212/WNL.60.1.147 · DOI
  9. Dimmit, 2000, Selective serotonin receptor uptake inhibitors can reduce restless legs syndrome (letter), Arch Intern Med, 160, 712, 10.1001/archinte.160.5.712 · DOI
  10. Dorsey, 1996, Fluoxetine-induced sleep disturbance in depressed patients, Neuropsychopharmacology, 14, 437, 10.1016/0893-133X(95)00148-7 · DOI
  11. Ekbom, 1960, Restless legs syndrome, Neurology, 10, 868, 10.1212/WNL.10.9.868 · DOI
  12. Fawcett, 1990, Time-related predictors of suicide in major affective disorder, Am J Psychiatry, 147, 1189, 10.1176/ajp.147.9.1189 · DOI
  13. Hargrave, 1998, Restless legs syndrome exacerbated by sertraline (letter), Psychosomatics, 39, 177, 10.1016/S0033-3182(98)71370-2 · DOI
  14. Hening, 2004, Udine special section: Subjective and objective criteria in the diagnosis of the restless legs syndrome, Sleep Medicine, 5, 285, 10.1016/j.sleep.2004.01.006 · DOI
  15. Kraus, 1999, Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine, J Clin Psychopharmacol, 19, 478, 10.1097/00004714-199910000-00017 · DOI
  16. Lutz, 1978, Restless legs, anxiety and caffeinism, J Clin Psychiatry, 39, 693
  17. Markkula, 1997, Mianserin and restless legs, Int Clin Psychopharmacol, 12, 53, 10.1097/00004850-199701000-00008 · DOI
  18. Milne, 1992, Akathisia associated with carbamazepine therapy, N Zld Med J, 105, 182
  19. Nader, 2007, Restless legs syndrome induced by citalopram: A psychiatric emergency?, Gen Hosp Psych, 29, 72, 10.1016/j.genhosppsych.2006.10.006 · DOI
  20. Ohayon, 2002, Prevalence of restless legs syndrome and periodic limb movement disorder in the general population, J Psychosom Res, 53, 547, 10.1016/S0022-3999(02)00443-9 · DOI
  21. O’Sullivan, 1993, H2 antagonists, restless legs syndrome, and movement disorders, Psychosomatics, 34, 530, 10.1016/S0033-3182(93)71830-7 · DOI
  22. Pae, 2004, Re-administration of mirtazapine could overcome previous mirtazapine-associated restless legs syndrome?, Psychiatry Clin Neurosci, 58, 669, 10.1111/j.1440-1819.2004.01319.x · DOI
  23. Paik, 1989, Mianserin-induced restless legs syndrome, Br J Psychiatry, 155, 415, 10.1192/bjp.155.3.415 · DOI
  24. Picchietti, 2005, Restless legs syndrome, periodic limb movements in sleep, and depression, Sleep, 28, 891
  25. Sanz-Fuentenebro, 1996, Restless legs syndrome and paroxetine, Acta Psychiatr Scand, 94, 482, 10.1111/j.1600-0447.1996.tb09896.x · DOI
  26. Teive, 2002, Worsening of autosomal dominant restless legs syndrome after use of mirtazapine: Case report, Arch Neuropsychiatr, 60, 1025
  27. Terao, 1991, Restless legs syndrome induced by lithium, Biol Psychiatry, 30, 1167, 10.1016/0006-3223(91)90185-O · DOI
  28. Walters, 1995, The International Restless Legs Syndrome Study Group: Towards a better definition of the restless legs syndrome, Mov Disord, 10, 634, 10.1002/mds.870100517 · DOI
  29. Ware, 1984, Nocturnal myoclonus and tricyclic antidepressants, Sleep Research, 13, 72
  30. Wetter, 2002, Restless legs syndrome probably induced by risperidone treatment, Pharmacopsychiatry, 35, 109, 10.1055/s-2002-31514 · DOI
  31. Winkelmann, 2005, Anxietas Tibiarum: Depression and anxiety disorders in patients with restless legs syndrome, J Neurol, 252, 67, 10.1007/s00415-005-0604-7 · DOI · Paper page
  32. Yang, 2005, Antidepressants and periodic leg movements of sleep, Biol Psychiatry, 58, 510, 10.1016/j.biopsych.2005.04.022 · DOI
  33. Yeragani, 1988, Tricyclics, akathisia, and jitteriness, J Clin Psychopharmacol, 8, 295, 10.1097/00004714-198808000-00024 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rottach, K. G., Schaner, B. M., Kirch, M. H., Zivotofsky, A. Z., Teufel, L. M., Gallwitz, T., & Messer, T.
Affiliations
  • Bar-Ilan University (IL)
  • Juzo (Germany) (DE)
  • Bezirkskrankenhaus Augsburg (DE)
ORCID
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2008-11
Volume
43
Issue
1
Pages
70-75
ISSN
0022-3956 (ISSN-L)
DOI
10.1016/j.jpsychires.2008.02.006
OpenAlex
W2003299753
Cited by
249
References
2
Citations by year
2026: 2 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 12 · 2017: 12 · 2016: 16 · 2015: 18 · 2014: 23 · 2013: 29 · 2012: 18
FWCI
11.06
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Psychiatric Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Restless Legs Syndrome Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
restless legs syndrome, second-generation antidepressants, selective serotonin reuptake inhibitors, mirtazapine, reboxetine, adverse drug reactions, venlafaxine, duloxetine, escitalopram, sertraline, fluoxetine, paroxetine, citalopram
MeSH terms
Reboxetine, Mirtazapine, Acute Disease, Adult, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Female, Humans, Male, Mianserin, Middle Aged, Morpholines, Prospective Studies, Restless Legs Syndrome, Citalopram, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review